bpc-157 not approved by fda statement Understanding the Legal Risks of and Other Unapproved Peptides – Holt Law FDA advisers back first four

A clinical study on modified growth hormone releasing factor (CJC-1295) demonstrated sustained increases in GH and IGF-1 levels following repeated dosing with a favorable safety profile, supporting the use of consistent dosing over multi-week protocols

However, this short window does not limit therapeutic benefit because BPC-157 triggers lasting biological changes rather than needing to remain constantly present

A common research-planning SubQ start is 50 mg (about 0.50 mL at 100 mg/mL) once weekly or three times weekly, then escalate by ~25 mg as tolerated

Cell Signaling: NAD+ participates in signaling pathways that regulate cell survival, aging, and stress responses

Pickart L, Margolina A